36C25923Q0583 0002.docx

Amendment to a Previous Combined Solicitation

Amendment to a Previous Combined Solicitation

GENERAL INFORMATION

Network Contracting Office

NCO 19

6162 South Willow Drive, Suite 300 Greenwood Village CO 80111

POINT OF CONTACT*

Contract Specialist Noaa Lanotte Noaa.Lanotte@va.gov 303-712-5794

PLACE OF PERFORMANCE

Eastern Colorado Healthcare System

Rocky Mountain Regional VAMC

1700 North Wheeling Street

Aurora CO

ADDITIONAL INFORMATION

AGENCY’S URL

URL DESCRIPTION

AGENCY CONTACT’S EMAIL ADDRESS

EMAIL DESCRIPTION

DESCRIPTION

The purpose of this amendment is to notify all offerors of the following:

· The due date for offers has been extended until July 3rd, 2023, at 10AM MT.

· Estimated Project Duration has been updated to 1 Year (12 Months).

· Please see questions and answers below.

Questions and Answers

1. Do you have any more details on the types of compounds involved and/or the synthesis steps required?

0. No. We require the vendor to help with the design. Of the compounds designed by the vendor, we will do the docking into our target. Docking will identify a few compounds that will be synthesized. The vendor will assist with design and synthesis of the identified compounds. The vendor will test the identified compounds against a library of bacterial pathogens. We plan to synthesize a handful of compounds, learn from the microbiological assays done by the vendor and by the Vazquez-Torres lab enzymatic and biochemical assays, and repeat one or two iterations of synthesis and testing. The vendor should synthesize a total of 23 compounds.

1. Will these compounds require verification of the synthesized structure (via NMR and mass spec etc. measurements)?

1. Yes

1. If you don’t have additional details on the types of compounds, can we just assume that the project will require 4 months of labor (ie, the estimated project duration) from a PhD Chemist?

2. We believe it will be more realistic to synthesize the 23 compounds in a 12-month period.

1. Would we have access to either a docking model or an Xray co-crystal structure of the hit bound to DksA?

3. Yes

1. Would we have access to previous SAR (including structurally related inactive compounds)? With this info, we could certainly design quality analogs, although the numbers requested are surprisingly low.

4. Yes

1. It would also be useful to know if heterocyclic amide replacements have been tried.

5. No, they have not.

1. Would there be an expectation of any iterations of SAR within the 23? (This could merit discussion of expectations.)

6. Yes, iterations would be the most effective way to move forward per #1.

1. Does contractor need to propose ~ 100 analogs based on the traditional medicinal chemistry approach to submit with the initial quote?

7. Yes, or as many as possible.

1. For the primary microbiological screening would ESKAPE Pathogens panel is sufficient or additional bacterial strains needed to be included to assess activities.

8. ESKAPA pathogens as well as others of clinical significance.

Page 1 of

Amendment to a Previous Combined Solicitation